Somatic PTPN11 mutations in childhood acute myeloid leukaemia

Marco Tartaglia, Simone Martinelli, Ivano Iavarone, Giovanni Cazzaniga, Monica Spinelli, Emanuela Giarin, Valentina Petrangeli, Claudio Carta, Riccardo Masetti, Maurizio Aricò, Franco Locatelli, Giuseppe Basso, Mariella Sorcini, Andrea Pession, Andrea Biondi

Research output: Contribution to journalArticle

Abstract

Somatic mutations in PTPN11, the gene encoding the transducer SHP-2, have emerged as a novel class of lesions that upregulate RAS signalling and contribute to leukaemogenesis. In a recent study of 69 children and adolescents with de novo acute myeloid leukaemia (AML), we documented a non-random distribution of PTPN11 mutations among French-American-British (FAB) subtypes. Lesions were restricted to FAB-M5 cases, where they were relatively common (four of 12 cases). Here, we report on the results of a molecular screening performed on 181 additional unselected patients, enrolled in participating institutions of the Associazione Italiana Ematologia Oncologia Pediatrica-AML Study Group, to provide a more accurate picture of the prevalence, spectrum and distribution of PTPN11 mutations in childhood AML and to investigate their clinical relevance. We concluded that PTPN11 defects do not represent a frequent event in this heterogeneous group of malignancies (4-4%), although they recur in a considerable percentage of patients with FAB-M5 (18%). PTPN11 lesions rarely occur in other subtypes. Within the FAB-M5 group no clear association of PTPN11 mutations with any clinical variable was evident. Nearly two third of the patients with this subtype were found to harbour an activating mutation in PTPN11, NRAS, KRAS2 or FLT3.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalBritish Journal of Haematology
Volume129
Issue number3
DOIs
Publication statusPublished - May 2005

Fingerprint

Acute Myeloid Leukemia
Mutation
Transducers
Up-Regulation
Genes
Neoplasms

Keywords

  • Childhood acute myeloid leukaemia
  • FAB-M5 subtype
  • PTPN11
  • SHP-2
  • Somatic mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Tartaglia, M., Martinelli, S., Iavarone, I., Cazzaniga, G., Spinelli, M., Giarin, E., ... Biondi, A. (2005). Somatic PTPN11 mutations in childhood acute myeloid leukaemia. British Journal of Haematology, 129(3), 333-339. https://doi.org/10.1111/j.1365-2141.2005.05457.x

Somatic PTPN11 mutations in childhood acute myeloid leukaemia. / Tartaglia, Marco; Martinelli, Simone; Iavarone, Ivano; Cazzaniga, Giovanni; Spinelli, Monica; Giarin, Emanuela; Petrangeli, Valentina; Carta, Claudio; Masetti, Riccardo; Aricò, Maurizio; Locatelli, Franco; Basso, Giuseppe; Sorcini, Mariella; Pession, Andrea; Biondi, Andrea.

In: British Journal of Haematology, Vol. 129, No. 3, 05.2005, p. 333-339.

Research output: Contribution to journalArticle

Tartaglia, M, Martinelli, S, Iavarone, I, Cazzaniga, G, Spinelli, M, Giarin, E, Petrangeli, V, Carta, C, Masetti, R, Aricò, M, Locatelli, F, Basso, G, Sorcini, M, Pession, A & Biondi, A 2005, 'Somatic PTPN11 mutations in childhood acute myeloid leukaemia', British Journal of Haematology, vol. 129, no. 3, pp. 333-339. https://doi.org/10.1111/j.1365-2141.2005.05457.x
Tartaglia, Marco ; Martinelli, Simone ; Iavarone, Ivano ; Cazzaniga, Giovanni ; Spinelli, Monica ; Giarin, Emanuela ; Petrangeli, Valentina ; Carta, Claudio ; Masetti, Riccardo ; Aricò, Maurizio ; Locatelli, Franco ; Basso, Giuseppe ; Sorcini, Mariella ; Pession, Andrea ; Biondi, Andrea. / Somatic PTPN11 mutations in childhood acute myeloid leukaemia. In: British Journal of Haematology. 2005 ; Vol. 129, No. 3. pp. 333-339.
@article{65c4aea1973843b1a0241272edf61ae9,
title = "Somatic PTPN11 mutations in childhood acute myeloid leukaemia",
abstract = "Somatic mutations in PTPN11, the gene encoding the transducer SHP-2, have emerged as a novel class of lesions that upregulate RAS signalling and contribute to leukaemogenesis. In a recent study of 69 children and adolescents with de novo acute myeloid leukaemia (AML), we documented a non-random distribution of PTPN11 mutations among French-American-British (FAB) subtypes. Lesions were restricted to FAB-M5 cases, where they were relatively common (four of 12 cases). Here, we report on the results of a molecular screening performed on 181 additional unselected patients, enrolled in participating institutions of the Associazione Italiana Ematologia Oncologia Pediatrica-AML Study Group, to provide a more accurate picture of the prevalence, spectrum and distribution of PTPN11 mutations in childhood AML and to investigate their clinical relevance. We concluded that PTPN11 defects do not represent a frequent event in this heterogeneous group of malignancies (4-4{\%}), although they recur in a considerable percentage of patients with FAB-M5 (18{\%}). PTPN11 lesions rarely occur in other subtypes. Within the FAB-M5 group no clear association of PTPN11 mutations with any clinical variable was evident. Nearly two third of the patients with this subtype were found to harbour an activating mutation in PTPN11, NRAS, KRAS2 or FLT3.",
keywords = "Childhood acute myeloid leukaemia, FAB-M5 subtype, PTPN11, SHP-2, Somatic mutation",
author = "Marco Tartaglia and Simone Martinelli and Ivano Iavarone and Giovanni Cazzaniga and Monica Spinelli and Emanuela Giarin and Valentina Petrangeli and Claudio Carta and Riccardo Masetti and Maurizio Aric{\`o} and Franco Locatelli and Giuseppe Basso and Mariella Sorcini and Andrea Pession and Andrea Biondi",
year = "2005",
month = "5",
doi = "10.1111/j.1365-2141.2005.05457.x",
language = "English",
volume = "129",
pages = "333--339",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Somatic PTPN11 mutations in childhood acute myeloid leukaemia

AU - Tartaglia, Marco

AU - Martinelli, Simone

AU - Iavarone, Ivano

AU - Cazzaniga, Giovanni

AU - Spinelli, Monica

AU - Giarin, Emanuela

AU - Petrangeli, Valentina

AU - Carta, Claudio

AU - Masetti, Riccardo

AU - Aricò, Maurizio

AU - Locatelli, Franco

AU - Basso, Giuseppe

AU - Sorcini, Mariella

AU - Pession, Andrea

AU - Biondi, Andrea

PY - 2005/5

Y1 - 2005/5

N2 - Somatic mutations in PTPN11, the gene encoding the transducer SHP-2, have emerged as a novel class of lesions that upregulate RAS signalling and contribute to leukaemogenesis. In a recent study of 69 children and adolescents with de novo acute myeloid leukaemia (AML), we documented a non-random distribution of PTPN11 mutations among French-American-British (FAB) subtypes. Lesions were restricted to FAB-M5 cases, where they were relatively common (four of 12 cases). Here, we report on the results of a molecular screening performed on 181 additional unselected patients, enrolled in participating institutions of the Associazione Italiana Ematologia Oncologia Pediatrica-AML Study Group, to provide a more accurate picture of the prevalence, spectrum and distribution of PTPN11 mutations in childhood AML and to investigate their clinical relevance. We concluded that PTPN11 defects do not represent a frequent event in this heterogeneous group of malignancies (4-4%), although they recur in a considerable percentage of patients with FAB-M5 (18%). PTPN11 lesions rarely occur in other subtypes. Within the FAB-M5 group no clear association of PTPN11 mutations with any clinical variable was evident. Nearly two third of the patients with this subtype were found to harbour an activating mutation in PTPN11, NRAS, KRAS2 or FLT3.

AB - Somatic mutations in PTPN11, the gene encoding the transducer SHP-2, have emerged as a novel class of lesions that upregulate RAS signalling and contribute to leukaemogenesis. In a recent study of 69 children and adolescents with de novo acute myeloid leukaemia (AML), we documented a non-random distribution of PTPN11 mutations among French-American-British (FAB) subtypes. Lesions were restricted to FAB-M5 cases, where they were relatively common (four of 12 cases). Here, we report on the results of a molecular screening performed on 181 additional unselected patients, enrolled in participating institutions of the Associazione Italiana Ematologia Oncologia Pediatrica-AML Study Group, to provide a more accurate picture of the prevalence, spectrum and distribution of PTPN11 mutations in childhood AML and to investigate their clinical relevance. We concluded that PTPN11 defects do not represent a frequent event in this heterogeneous group of malignancies (4-4%), although they recur in a considerable percentage of patients with FAB-M5 (18%). PTPN11 lesions rarely occur in other subtypes. Within the FAB-M5 group no clear association of PTPN11 mutations with any clinical variable was evident. Nearly two third of the patients with this subtype were found to harbour an activating mutation in PTPN11, NRAS, KRAS2 or FLT3.

KW - Childhood acute myeloid leukaemia

KW - FAB-M5 subtype

KW - PTPN11

KW - SHP-2

KW - Somatic mutation

UR - http://www.scopus.com/inward/record.url?scp=20844439887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844439887&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05457.x

DO - 10.1111/j.1365-2141.2005.05457.x

M3 - Article

C2 - 15842656

AN - SCOPUS:20844439887

VL - 129

SP - 333

EP - 339

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -